Moore Alissa, El-Zein Mariam, Burchell Ann N, Tellier Pierre-Paul, Coutlée François, Franco Eduardo L
Division of Cancer Epidemiology, Gerald Bronfman Department of Oncology, McGill University, Montréal, Quebéc, Canada.
MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada; Department of Family and Community Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
J Clin Virol. 2025 Apr;177:105779. doi: 10.1016/j.jcv.2025.105779. Epub 2025 Mar 11.
Understanding human papillomavirus (HPV) transmission dynamics within couples is necessary for optimal vaccine catch-up strategies. We used data from the Transmission Reduction and Prevention with HPV Vaccination (TRAP-HPV) study to estimate sex-specific incidence and transmission rates.
The TRAP-HPV study enrolled (2014-2022) new (≤6 months) heterosexual couples aged 18+ in Montreal, Canada. The study employed a 2 × 2 factorial design. Participants (n = 308) were randomized into four groups: neither partner vaccinated against HPV, only the male partner vaccinated against HPV, only the female partner vaccinated against HPV, or both partners vaccinated against HPV. Genital samples, collected at 0, 2, 4, 6, 9, and 12 months, were genotyped for 36 HPV types. We performed time-to-event analyses for vaccine-targeted HPVs (6/11/16/18/31/33/45/52/58) and HPVs phylogenetically related (35/39/44/59/67/68/70) and unrelated (26/34/40/42/51/53/54/56/61/62/66/69/71/72/73/81/82/83/84/89) to vaccine-targeted types, using type-specific HPV infections as the unit of analysis.
Participants had a mean age of 25.5 years (SD 6.0), and a median of 6 (IQR: 2-15) lifetime sexual partners. Among males, incidence rates (in events/1000 months) were 0.99 (95 % CI: 0.17-3.07) and 1.67 (95 % CI: 0.75-3.51) in the two groups with vaccinated males versus 2.42 (95 % CI: 0.97-7.63) and 3.35 (95 % CI: 1.95-6.30) in the groups with unvaccinated males. Results were similar for the three HPV groups.
There was no consistent pattern of protection against incident HPV detection in females and no indication that recent vaccination was associated with lower transmission in discordant couples or with protection for one's partner. Findings should not be generalized to younger populations.
了解人乳头瘤病毒(HPV)在伴侣间的传播动态对于优化疫苗补种策略至关重要。我们利用HPV疫苗接种减少和预防(TRAP-HPV)研究的数据来估计性别特异性发病率和传播率。
TRAP-HPV研究在加拿大蒙特利尔招募了(2014 - 2022年)年龄在18岁及以上的新(≤6个月)异性恋伴侣。该研究采用2×2析因设计。参与者(n = 308)被随机分为四组:伴侣双方均未接种HPV疫苗、仅男性伴侣接种HPV疫苗、仅女性伴侣接种HPV疫苗或伴侣双方均接种HPV疫苗。在0、2、4、6、9和12个月采集的生殖器样本针对36种HPV类型进行基因分型。我们针对疫苗靶向的HPV(6/11/16/18/31/33/45/52/58)以及与疫苗靶向类型在系统发育上相关(35/39/44/59/67/68/70)和不相关(26/34/40/42/51/53/54/56/61/62/66/69/71/72/73/81/82/83/84/89)的HPV进行了事件发生时间分析,以特定类型的HPV感染作为分析单位。
参与者的平均年龄为25.5岁(标准差6.0),终生性伴侣数中位数为6(四分位间距:2 - 15)。在男性中,男性接种疫苗的两组发病率(每1000人月发病数)分别为0.99(95%置信区间:0.17 - 3.07)和1.67(95%置信区间:0.75 - 3.51),而男性未接种疫苗的两组发病率分别为2.42(95%置信区间:0.97 - 7.63)和3.35(95%置信区间:1.95 - 6.30)。三个HPV组的结果相似。
在女性中,对于HPV新发感染的预防不存在一致的保护模式,并且没有迹象表明近期接种疫苗与不一致伴侣组中较低的传播率相关,或与对伴侣的保护相关。研究结果不应推广至更年轻人群。